Ceapro Logo.jpg
Ceapro Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
22 avr. 2021 09h05 HE | Ceapro Inc.
Maintained production operations during COVID-19 pandemic, providing customers with essential products and completing integration of manufacturing site, while ensuring the health and safety of...
Ceapro Logo.jpg
Ceapro Inc. Announces Successful Completion of Collaborative Research and Development Program with University of Alberta
08 avr. 2021 08h05 HE | Ceapro Inc.
– Project significantly advances broadening the application and utility of Ceapro’s proprietary, first-in-class technologies to develop innovative delivery systems composed of new chemical complexes –...
Ceapro Logo.jpg
Ceapro Inc. to Present at the H.C. Wainwright Global Life Sciences Conference
03 mars 2021 09h05 HE | Ceapro Inc.
EDMONTON, Alberta, March 03, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Logo.jpg
Ceapro Inc. to Present at NobleCon17
14 janv. 2021 09h00 HE | Ceapro Inc.
EDMONTON, Alberta, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Logo.jpg
Ceapro Inc. to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
08 janv. 2021 08h05 HE | Ceapro Inc.
EDMONTON, Alberta, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Logo.jpg
Ceapro Inc. Reports 2020 Third Quarter and Nine-Month Financial Results and Operational Highlights
27 nov. 2020 09h00 HE | Ceapro Inc.
– R&D activities focused on advancing the development of innovative delivery systems and yeast beta glucan as a potential inhalable therapeutic for COVID-19 – – Q3 2020 sales of $3,476,000...
Ceapro Logo.jpg
Ceapro Inc. Announces Increased Financial Contribution from National Research Council of Canada for Innovative PGX Technology Project
22 oct. 2020 08h05 HE | Ceapro Inc.
EDMONTON, Alberta, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Logo.jpg
Ceapro Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
14 sept. 2020 08h35 HE | Ceapro Inc.
EDMONTON, Alberta, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Logo.jpg
Ceapro Inc. Reports 2020 Second Quarter and Six-Month Financial Results and Operational Highlights
20 août 2020 09h05 HE | Ceapro Inc.
– Record second quarter sales of $4,666,000 compared to $3,054,000 for second quarter 2019, representing a 53% increase and highest quarterly sales in Company’s history – – R&D activities focused...
Ceapro Logo.jpg
Ceapro Inc. Provides Update on Development of an Inhalable Therapeutic for COVID-19
18 août 2020 08h05 HE | Ceapro Inc.
– First milestone successfully achieved in early stages of the ongoing research project with McMaster University – Confirmed capability of PGX Technology to optimize and standardize the size and...